Open Access. Powered by Scholars. Published by Universities.®

Public Health Commons

Open Access. Powered by Scholars. Published by Universities.®

Georgia Southern University

Kelly L. Sullivan

Intravenous immune globulin

Articles 1 - 1 of 1

Full-Text Articles in Public Health

Treatment Of Neurodegenerative Ataxias With Intravenous Immune Globulin, Theresa A. Zesiewicz, Seok Hun Kim, Kelly L. Sullivan, Jeannie Stephenson, Israt Jahan, Susan L. Perlman, Jessica D. Shaw, Tuan Vu, Clifton L. Gooch Jan 2014

Treatment Of Neurodegenerative Ataxias With Intravenous Immune Globulin, Theresa A. Zesiewicz, Seok Hun Kim, Kelly L. Sullivan, Jeannie Stephenson, Israt Jahan, Susan L. Perlman, Jessica D. Shaw, Tuan Vu, Clifton L. Gooch

Kelly L. Sullivan

Background: Neurodegenerative ataxias, including spinocerebellar ataxias (SCAs), are progressive diseases without effective treatment. There is preclinical evidence that inflammation may contribute to neuronal injury in several neurodegenerative ataxias. Intravenous immune globulin (IVIG) is a therapeutic modality that is used as treatment of several autoimmune and inflammatory disorders.
Methods: The primary objective of this open-label pilot study was to assess the effect of IVIG on neurodegenerative ataxias as measured by total scale for the assessment and rating of ataxia (SARA) score. Three patients received IVIG (2 g/kg of body weight, divided over 5 days) once monthly for 3 months, and were …